Omeros Corporation (NASDAQ:OMER - Free Report) - Investment analysts at HC Wainwright raised their FY2027 earnings estimates for Omeros in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings of $0.33 per share for the year, up from their prior forecast of $0.24. HC Wainwright has a "Buy" rating and a $33.00 price objective on the stock. The consensus estimate for Omeros' current full-year earnings is ($0.37) per share.
Omeros (NASDAQ:OMER - Get Free Report) last posted its earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. The firm had revenue of $35.93 million during the quarter, compared to the consensus estimate of $37.28 million.
Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald restated an "overweight" rating and set a $22.00 target price on shares of Omeros in a research report on Wednesday, October 14th. Weiss Ratings upgraded Omeros from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Finally, Wall Street Zen upgraded Omeros from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $30.33.
View Our Latest Stock Report on OMER
Omeros Stock Down 16.5%
Omeros stock opened at $13.92 on Wednesday. The stock has a 50-day simple moving average of $18.12 and a 200 day simple moving average of $13.77. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 14.50 and a beta of 2.96. Omeros has a 12-month low of $6.70 and a 12-month high of $21.24.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in OMER. Algert Global LLC bought a new position in shares of Omeros during the 3rd quarter worth approximately $1,234,000. New York State Common Retirement Fund raised its stake in Omeros by 25.6% in the 3rd quarter. New York State Common Retirement Fund now owns 26,013 shares of the biopharmaceutical company's stock valued at $495,000 after acquiring an additional 5,300 shares during the period. Aquatic Capital Management LLC bought a new stake in Omeros in the 3rd quarter valued at $733,000. Goldman Sachs Group Inc. lifted its holdings in Omeros by 151.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 395,032 shares of the biopharmaceutical company's stock valued at $7,521,000 after purchasing an additional 238,024 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Omeros during the 3rd quarter valued at $3,387,000. Institutional investors and hedge funds own 48.79% of the company's stock.
Insider Buying and Selling
In other Omeros news, VP Peter Cancelmo sold 25,000 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the transaction, the vice president owned 200 shares of the company's stock, valued at approximately $3,708. This represents a 99.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Thomas Cable sold 15,000 shares of the firm's stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $18.45, for a total value of $276,750.00. Following the transaction, the director owned 35,067 shares in the company, valued at approximately $646,986.15. This trade represents a 29.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 100,906 shares of company stock valued at $1,904,955 in the last three months. 10.50% of the stock is currently owned by company insiders.
More Omeros News
Investors following OMER have been watching these news items:
About Omeros
(
Get Free Report)
Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.